KUALA LUMPUR: Duopharma Biotech Bhd continues to have a bullish outlook for its group performance next year, leveraging the country’s higher allocation for healthcare under Budget 2020.
Group managing director Leonard Ariff Abdul Shatar said the increase in the allocation for the Health Ministry reflected the government’s commitment to ensure sufficient medicine supply for Malaysians.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!